Senti Biosciences Holdings, Inc.
As of Oct 22, 2026, Senti Biosciences Holdings is in Stage 4, the downtrend phase, now in week 14 (since Jul 17, 2026). It closed at $0.19, 92.0% below its 52-week high and below its 200-day average, which is falling.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SNTI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SNTI among Biotechnology513th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …513 | SNTI | Stage 4 · wk 14 | 7 | −43.5% |
Senti Biosciences Holdings: quick answers
What stage is Senti Biosciences Holdings in?
As of Oct 22, 2026, Senti Biosciences Holdings (SNTI) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 17, 2026 and is in week 14. What the four stages mean
Is Senti Biosciences Holdings in an uptrend?
No. Senti Biosciences Holdings is in a Stage 4 downtrend. It trades 74.6% below its 200-day average, which is falling.
How far is Senti Biosciences Holdings from its 52-week high?
Senti Biosciences Holdings closed at $0.19 on Oct 22, 2026, 92.0% below its 52-week high of $2.39. Its 52-week low is $0.19.
How has Senti Biosciences Holdings performed over the past year?
As of Oct 22, 2026, Senti Biosciences Holdings is down 90.7% over the past year and down 82.6% so far in 2026.
Which sector and industry is Senti Biosciences Holdings in?
Senti Biosciences Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.